Tempus AI shares surged approximately 12% in pre-market trading on January 12, 2026, following the release of preliminary forecasts for 2025 and a record contract-value report. The company’s stock reached $74.34 in the premarket session, buoyed by expectations as investors look forward to presentations at the J.P. Morgan Healthcare Conference and the upcoming U.S. inflation report.
In an SEC filing, Tempus projected full-year revenue of around $1.27 billion for 2025, marking an impressive 83% increase from the previous year. This growth was driven largely by advancements in diagnostics and a significant boost in data licensing. Diagnostics revenue alone soared to approximately $955 million, representing a remarkable 111% year-over-year increase, while data and applications contributed an additional $316 million, up 31%. The company also reported fourth-quarter revenue nearing $367 million, reflecting an 83% year-on-year growth.
“We enter 2026 in an exceptionally strong position,” stated Eric Lefkofsky, founder and CEO of Tempus. The company also noted a total contract value (TCV) exceeding $1.1 billion as of December 31, indicating a robust pipeline of future revenue. The TCV reflects the potential worth of signed contracts, including options, prior to revenue recognition. The company reported a net revenue retention rate of approximately 126%, signaling strong customer spending growth year-over-year. In 2025, Tempus secured data agreements with over 70 clients, including major stakeholders such as AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, and Merck. “2025 was a record year for our Data and applications business,” remarked Jim Rogers, CFO of Tempus.
Adding to its growth narrative, Tempus recently announced a partnership with Northwestern Medicine aimed at expanding genomic testing for cancer patients, including those diagnosed at earlier stages. The collaboration will see Tempus provide advanced tests such as next-generation sequencing, liquid biopsies, and minimal residual disease (MRD) testing. “Northwestern Medicine will now offer next-generation sequencing to patients with earlier-stage cancers,” said Dr. Howard Chrisman, president and CEO of Northwestern Memorial HealthCare.
In a contrasting market atmosphere, while Tempus experienced a notable rise, other tech giants like Nvidia and Alphabet saw their stocks decline in premarket activity. This divergence comes amid a generally volatile morning for growth stocks, with Nasdaq 100 futures dipping close to 1% as investors grapple with uncertainties regarding the Federal Reserve’s monetary policy and gear up for the upcoming earnings season.
However, caution accompanies Tempus’ optimistic outlook. The company has indicated that its reported figures are preliminary and unaudited, leaving open the possibility of adjustments as the fiscal year closes. Any potential decline in testing volume or a weakening of data-licensing demand could quickly alter the positive sentiment surrounding its results, particularly in light of rate volatility re-entering the economic landscape.
As Tempus prepares to address questions at the J.P. Morgan Healthcare Conference, management will likely face scrutiny regarding demand, pricing, and margins for 2026. Investors are particularly alerted to the U.S. consumer price index report for December, set to be released at 8:30 a.m. ET on Tuesday. This critical data point could significantly influence rate expectations and impact high-multiple AI stocks, creating potential volatility for the sector.
Overall, Tempus AI’s strong preliminary results and strategic partnerships position the company favorably within the competitive landscape of the healthcare technology sector, but the broader economic context will undoubtedly be a focal point for both investors and analysts in the coming weeks.
See also
Local Governments Must Balance AI Innovation and Regulation to Avoid Algorithmic Bias Risks
Google DeepMind CTO Kavukcuoglu: AGI Development Lacks Clear Recipe Despite Progress
AI Revolutionizes Learning Leadership: 69% of L&D Pros See Major Upskilling Potential by 2026
Haut.AI Unveils Expert Advisory Board to Accelerate AI-Driven Beauty Personalization
Amazon Sues Perplexity AI, Threatening Future of Digital Advertising and Shopping Agents
